With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...

After adjustment for confounding variables, researchers found no increased suicide risk for GLP-1 receptor agonists versus DPP-4 inhibitors or SGLT-2 inhibitors.

GLP-1 agonists may be protective against hip fracture when administered for the treatment of type 2 diabetes, according to ...

Beyond type 2 diabetes and weight loss, GLP-1 agonists can also help lower blood pressure, improve lipid disorders, reduce inflammation and improve heart health. With such advantages, the demand ...

For patients with type 2 diabetes, glucagon-like peptide-1 receptor agonist use is associated with a reduced risk for developing hematologic cancers compared with insulin and metformin use.

That is perhaps why there has been so much buzz surrounding the class of drug known as a GLP-1 agonist. Medications with the brand names Ozempic, Wegovy, Zepbound, and Mounjaro have garnered ...

When Jenni* started using a medication called liraglutide to lose weight, she noticed changes not just in her appetite, but in how she thought about food. Where the smell of hot chips in the deep ...

Preoperative glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is not associated with short-term postoperative aspiration pneumonia, according to a study published online March 4 in JAMA ...

However, for crude incidence rates there was an increased incidence of suicidality with GLP-1 receptor agonist vs DPP-4 inhibitor use; 3.9 vs 1.8 per 1000 person-years. HealthDay News — Glucagon ...

HealthDay News — For patients with type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced risk for developing hematologic cancers compared ...